ArticleFrontiers in oncology2026
External validation and updating of NTCP models for radiation pneumonitis: QUANTEC, Appelt, and a local simplified model.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To externally evaluate and update the QUANTEC and Appelt NTCP models for radiation pneumonitis (RP) in lung cancer patients treated with contemporary IMRT and multimodal therapy, and to preliminarily validate a simplified local model in an independent cohort. Methods: We retrospectively analyzed 580 lung cancer patients treated with thoracic IMRT between 2018 and 2023 as the development cohort. The QUANTEC and Appelt models were evaluated and locally updated using a closed testing procedure to determine the least extensive revision required. Clinical and DVH variables were standardized, and smoking status and pulmonary comorbidity were recoded according to published definitions. A final simplified local model (Model D) was developed using BIC-guided multivariable logistic regression with regularization. Performance was assessed by AUC, Brier score, calibration-in-the-large (CITL), calibration slope, Hosmer-Lemeshow test, and decision curve analysis. External validation of Model D was performed in 100 patients from an independent center using fixed coefficients. Results: Both the QUANTEC and Appelt models showed substantial calibration bias in the local cohort, with systematic underestimation of RP risk. Updating improved calibration as expected, with little change in discrimination. Model D, incorporating age, stage, smoking status, tumor location, pulmonary comorbidity, NLR, SII, V30, and MLD, showed the best apparent overall performance in the development cohort (AUC 0.708, Brier 0.215, CITL = 0, slope = 1, Hosmer-Lemeshow P = 0.599). In the external cohort, discrimination and prediction error were similar (AUC 0.718, 95% CI 0.576-0.831; Brier 0.207), although absolute RP risk was overestimated (CITL = -1.043, slope = 1.133, Hosmer-Lemeshow P < 0.001). Conclusions: The original QUANTEC and Appelt models underestimated RP risk in this contemporary IMRT cohort. Updating improved calibration, whereas discrimination changed little. Model D showed better apparent overall performance and preserved ranking ability in an independent external cohort. Calibration drift across centers suggests that simple recalibration may improve absolute risk estimation in new settings. Clinical trial registration: https://www.chictr.org.cn/hvshowproject.html?id=276191&v=1.1, identifier ChiCTR2500102055.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.